中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(5): 1101-1108

Impact of portal vein tumor thrombus classification on rebleeding in hepatocellular carcinoma patients with esophagogastric variceal bleeding

DOI: 10.12449/JCH260515

  • Department of Gastroenterology，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Project Assignment of Beijing Municipal Hospital Scientific Research Training Program (PX2023065);

Beijing Research Ward Excellence Program (BRWEP2024W102170111)

More Information
  • Corresponding author: LIANG Xiuxia， yliangxiuxia@163.com （ORCID： 0009-0008-3282-1758）
  • Received Date: 2025-12-05
  • Accepted Date: 2026-03-05
  • Published Date: 2026-05-25
    Abstract
  •   Objective  To investigate the impact of portal vein tumor thrombus （PVTT） classification on rebleeding in hepatocellular carcinoma （HCC） patients with different PVTT subtypes and esophagogastric variceal bleeding （EGVB）， and to provide a reference for formulating rational treatment regimens for such patients.  Methods  A retrospective study was performed for 130 patients with HCC and PVTT who were treated due to EGVB in Beijing Ditan Hospital， Capital Medical University， from July 2020 to January 2025， and according to whether endoscopic treatment was performed， the patients were divided into endoscopic treatment group with 97 patients and conservative treatment group with 33 patients. Demographic and clinical data were collected from all patients， and the two groups were compared in terms of hemostasis success rate and rebleeding rate. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to estimate the cumulative incidence rate of rebleeding in patients with different subtypes of PVTT. Propensity score matching （PSM） was performed for the endoscopic treatment group and the conservative treatment group to balance the baseline data of the two groups. The Cox proportional hazards model was used to perform univariate and multivariate analyses and identify independent risk factors for rebleeding.  Results  The endoscopic treatment group had a significantly lower cumulative rebleeding rate within 6 months than the conservative treatment group （35.1% vs 57.6%， hazard ratio ［HR］=0.480， 95% confidence interval ［CI］： 0.272—0.851， P=0.019）. The PVTT Ⅲ—Ⅳ group had a significantly higher cumulative rebleeding rate within 6 months than the PVTT Ⅱ group （52.2% vs 37.5%， HR=1.744， 95%CI： 1.008 — 3.018， P=0.022）. After PSM， there was no significant difference in rebleeding rate between the endoscopic treatment group and the conservative treatment group （38.1% vs 14.3%，HR=1.500，95%CI：0.125 — 2.002， P=0.588）， while the PVTT Ⅲ—Ⅳ group had a significantly higher cumulative rebleeding rate than the PVTT Ⅱ group （58.8% vs 12.5%，HR=1.561，95%CI：1.195 — 12.499，P=0.033）. The multivariate Cox regression analysis showed that PVTT subtype （HR=1.412， 95%CI： 0.998 — 1.997， P=0.049）， platelet count （HR=1.006， 95%CI： 1.001 — 1.010， P=0.021）， C-reactive protein （HR=1.011， 95%CI： 1.001 — 1.021， P=0.026）， and ascites （HR=1.803， 95%CI： 1.059 — 3.068， P=0.030） were independent risk factors for rebleeding.  Conclusion  For HCC patients with PVTT and EGVB， endoscopic treatment can successfully achieve hemostasis， while it fails to significantly reduce rebleeding rates. PVTT classification can affect the risk of rebleeding， and patients with PVTT types Ⅲ—Ⅳ have a relatively high rebleeding rate.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [2]
    KUDO M, IZUMI N, ICHIDA T, et al. Report of the 19th follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 2016, 46( 5): 372- 390. DOI: 10.1111/hepr.12697.
    [3]
    MÄHRINGER-KUNZ A, STEINLE V, DÜBER C, et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?[J]. Liver Int, 2019, 39( 2): 324- 331. DOI: 10.1111/liv.13988.
    [4]
    QIU GT, XIE KL, JIN ZX, et al. The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus[J]. Biosci Trends, 2021, 15( 3): 148- 154. DOI: 10.5582/bst.2021.01173.
    [5]
    HAN ML, CHEN CC, KUO SH, et al. Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis[J]. J Gastroenterol Hepatol, 2014, 29( 2): 344- 351. DOI: 10.1111/jgh.12341.
    [6]
    MA JL, HE LL, LI P, et al. Clinical features and outcomes of repeated endoscopic therapy for esophagogastric variceal hemorrhage in cirrhotic patients: Ten-year real-world analysis[J]. Gastroenterol Res Pract, 2020, 2020: 5747563. DOI: 10.1155/2020/5747563.
    [7]
    CHENG SQ, WU MC, CHEN H, et al. A study on imagination features of tumor thrombi in the portal vein of primary liver cancer[J]. Chin J Gen Surg, 2004, 19( 4): 200- 201. DOI: 10.3760/j.issn: 1007-631X.2004.04.002.

    程树群, 吴孟超, 陈汉, 等. 肝癌门静脉癌栓分型的影像学意义[J]. 中华普通外科杂志, 2004, 19( 4): 200- 201. DOI: 10.3760/j.issn: 1007-631X.2004.04.002.
    [8]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538. DOI: 10.3760/cmaj.cn501113-20220824-00436.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538. DOI: 10.3760/cmaj.cn501113-20220824-00436.
    [9]
    LEUNG JH, WANG SY, LEUNG HWC, et al. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: Patient-level network meta-analysis[J]. Front Oncol, 2024, 14: 1344798. DOI: 10.3389/fonc.2024.1344798.
    [10]
    WANG JP, WANG RM, ZHU XG. Three cases of radiotherapy for primary liver cancer with portal vein tumor thrombosis[J/CD]. Chin J Liver Dis(Electronic Version), 2025, 17( 3): 63- 67. DOI: 10.3969/j.issn.1674-7380.2025.03.010.

    王菊萍, 王润梅, 朱向高. 原发性肝癌合并门静脉癌栓放射治疗3例[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 3): 63- 67. DOI: 10.3969/j.issn.1674-7380.2025.03.010.
    [11]
    MU Y, GE NJ, WANG XH, et al. The efficacy CalliSpheres drug-eluding beads transcatheter arterial chemoembolization combined with hepatic artery infusion chemotherapy in the treatment of hepatocellular carcinoma complicated with portal vein tumor thrombus[J]. Clin J Med Offic, 2025, 53( 10): 1009- 1013, 1018. DOI: 10.16680/j.1671-3826.2025.10.04.

    穆亚, 葛乃建, 王鑫昊, 等. Callispheres可载药微球经导管动脉化疗栓塞联合肝动脉灌注化疗治疗肝细胞癌合并门静脉癌栓疗效[J]. 临床军医杂志, 2025, 53( 10): 1009- 1013, 1018. DOI: 10.16680/j.1671-3826.2025.10.04.
    [12]
    ABDELHAMED W, SHOUSHA H, EL-KASSAS M. Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?[J]. Liver Res, 2024, 8( 3): 141- 151. DOI: 10.1016/j.livres.2024.09.002.
    [13]
    LIU W, XU LX, XU F, et al. A retrospective analysis of the efficacy of endoscopic variceal ligation versus endoscopic tissue adhesive injection in the treatment of esophagogastric variceal bleeding[J]. Dig Dis, 2023, 41( 3): 468- 475. DOI: 10.1159/000528519.
    [14]
    HU YH, ZHOU M, LIU DL, et al. Risk factors for rebleeding after endoscopic injection of cyanoacrylate glue for gastric varices: A systematic review and meta-analysis[J]. Dig Dis Sci, 2024, 69( 8): 2890- 2903. DOI: 10.1007/s10620-024-08482-x.
    [15]
    HUANG XQ, ZOU DT, WANG HS, et al. Gastric variceal obstruction improves the efficacy of endoscopic management of esophageal variceal bleeding in GOV type I[J]. Endosc Int Open, 2024, 12( 8): E940- E946. DOI: 10.1055/a-2360-4490.
    [16]
    BRUSILOVSKAYA K, HOFER BS, SIMBRUNNER B, et al. Platelet function decreases with increasing severity of liver cirrhosis and portal hypertension-a prospective study[J]. Thromb Haemost, 2023, 123( 12): 1140- 1150. DOI: 10.1055/s-0043-1771187.
    [17]
    LIU H, CHEN P, JIANG B, et al. The value of platelet parameters and related scoring system in predicting esophageal varices and collateral veins in patients with liver cirrhosis[J]. J Clin Lab Anal, 2021, 35( 3): e23694. DOI: 10.1002/jcla.23694.
    [18]
    LI BB, LI Y, PENG Y, et al. Visual prediction models for predicting rebleeding events after the first esophageal variceal ligation[J]. Surg Endosc, 2025, 39( 6): 3576- 3586. DOI: 10.1007/s00464-025-11714-4.
    [19]
    TONON M, PIANO S. Cirrhosis and portal hypertension: How do we deal with ascites and its consequences[J]. Med Clin North Am, 2023, 107( 3): 505- 516. DOI: 10.1016/j.mcna.2022.12.004.
    [20]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [21]
    GIRI S, SUNDARAM S, JEARTH V, et al. Predictors of early bleeding after endoscopic variceal ligation for esophageal varices: A systematic review and meta-analysis[J]. Clin Exp Hepatol, 2022, 8( 4): 267- 277. DOI: 10.5114/ceh.2022.123096.
    [22]
    ZHAN JY, CHEN J, YU JZ, et al. Prognostic model for esophagogastric variceal rebleeding after endoscopic treatment in liver cirrhosis: A Chinese multicenter study[J]. World J Gastroenterol, 2025, 31( 2): 100234. DOI: 10.3748/wjg.v31.i2.100234.
    [23]
    CAZZANIGA M, DIONIGI E, GOBBO G, et al. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome[J]. J Hepatol, 2009, 51( 3): 475- 482. DOI: 10.1016/j.jhep.2009.04.017.
    [24]
    ICHIKAWA T, MACHIDA N, KANEKO H, et al. C-reactive protein can predict patients with cirrhosis at a high risk of early mortality after acute esophageal variceal bleeding[J]. Intern Med, 2019, 58( 4): 487- 495. DOI: 10.2169/internalmedicine.1447-18.
    [25]
    MA JL, HE LL, LI P, et al. Prognosis of endotherapy versus splenectomy and devascularization for variceal bleeding in patients with hepatitis B-related cirrhosis[J]. Surg Endosc, 2021, 35( 6): 2620- 2628. DOI: 10.1007/s00464-020-07682-6.
    [26]
    LV Y, QI XS, HE CY, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial[J]. Gut, 2018, 67( 12): 2156- 2168. DOI: 10.1136/gutjnl-2017-314634.
    [27]
    LIU J, LADBURY C, AMINI A, et al. Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis[J]. Radiat Oncol J, 2021, 39( 2): 113- 121. DOI: 10.3857/roj.2021.00213.
    [28]
    LI YY, WANG DC, ZHANG FT, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma(> 10 cm) with major portal vein tumor thrombosis: A multicenter propensity score matching analysis[J]. Front Immunol, 2025, 16: 1638173. DOI: 10.3389/fimmu.2025.1638173.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (31) PDF downloads(6) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return